AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future expansions expected. Click to read my ABBV update.

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns.

For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience portfolios led the results.